Dublin, March 15, 2018 -- The "Global Pediatrics Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Pediatrics Partnering 2012 to 2018 provides the full collection of Pediatrics disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Pediatrics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Pediatrics deals.
The report presents financial deal terms values for Pediatrics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Pediatrics partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Pediatrics partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pediatrics technologies and products.
Report scope
Global Pediatrics Partnering 2012 to 2018 includes:
- Trends in Pediatrics dealmaking in the biopharma industry since 2012
- Analysis of Pediatrics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Pediatrics deal contract documents
- Comprehensive access to over 3500 Pediatrics deal records
- The leading Pediatrics deals by value since 2012
- Most active Pediatrics dealmakers since 2012
In Global Pediatrics Partnering 2012 to 2018, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Pediatrics dealmaking
2.1. Introduction
2.2. Pediatrics partnering over the years
2.3. Pediatrics partnering by deal type
2.4. Pediatrics partnering by industry sector
2.5. Pediatrics partnering by stage of development
2.6. Pediatrics partnering by technology type
2.7. Pediatrics partnering by therapeutic indication
Chapter 3 - Financial deal terms for Pediatrics partnering
3.1. Introduction
3.2. Disclosed financials terms for Pediatrics partnering
3.3. Pediatrics partnering headline values
3.4. Pediatrics deal upfront payments
3.5. Pediatrics deal milestone payments
3.6. Pediatrics royalty rates
Chapter 4 - Leading Pediatrics deals and dealmakers
4.1. Introduction
4.2. Most active in Pediatrics partnering
4.3. List of most active dealmakers in Pediatrics
4.4. Top Pediatrics deals by value
Chapter 5 - Pediatrics contract document directory
5.1. Introduction
5.2. Pediatrics partnering deals where contract document available
Chapter 6 - Pediatrics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Pediatrics therapeutic target
Appendices
Appendix 1 - Directory of Pediatrics deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Pediatrics deals by deal type 2012 to 2018
Appendix 3 - Directory of Pediatrics deals by stage of development 2012 to 2018
Appendix 4 - Directory of Pediatrics deals by technology type 2012 to 2018
For more information about this report visit https://www.researchandmarkets.com/research/h9wh6w/global_pediatrics?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals, Pediatrics


Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Jetstar to Charge for Overhead Cabin Bags From February
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 



